Scrip asked 30 industry leaders to share their thoughts around what the biopharma industry will do – and what it needs to do – to advance diversity, equity and inclusion (DEI) this year. Their responses reflected the dual imperative to improve access to health for marginalized groups and to promote DEI within their own organizations and workforces.
“Diversity, equity and inclusion must be high priorities for multiple reasons,” said Gil Bashe managing partner, chair global health at...